Annual Report

Overview

The report describes Ascelia Pharma's 2025 progress toward FDA review of Orviglance, including NDA submission and formal acceptance, while Oncoral was prepared for Phase 2. It reports a Group of 10 full-time employees and net sales of SEK 0, reflecting the company's pre-revenue stage. Its sustainability ambition focuses on patient outcomes, an inclusive workplace, responsible governance and environmental sustainability, aligned with SDGs 3, 8 and 12. The Board approved the Annual Report on 9 April 2026.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services